Yoichi Sakurada

Chuo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 101 publications

Endophthalmitis Caused by α-Streptococcal Following Intravitreal Ranibizumab Biosimilar Administration Using a Prefilled Syringe.

Endophthalmitis Caused by α-Streptococcal Following Intravitreal Ranibizumab Biosimilar Administration Using a Prefilled Syringe.

Journal: Cureus

Published: February 24, 2026

Genetic factors associated with response to as-needed brolucizumab treatment for exudative age-related macular degeneration.

Genetic factors associated with response to as-needed brolucizumab treatment for exudative age-related macular degeneration.

Journal: Japanese journal of ophthalmology

Published: January 16, 2026

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy.

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: November 02, 2025

Recurrence of Intraocular Inflammation Following an Aflibercept 8-mg Injection in Eyes With a History of Intraocular Inflammation From Faricimab: A Case Report.

Recurrence of Intraocular Inflammation Following an Aflibercept 8-mg Injection in Eyes With a History of Intraocular Inflammation From Faricimab: A Case Report.

Journal: Cureus

Published: June 15, 2025

Genetic Factors Associated with Intraocular Inflammation After Brolucizumab Administration in Patients with Exudative Age-Related Macular Degeneration.

Genetic Factors Associated with Intraocular Inflammation After Brolucizumab Administration in Patients with Exudative Age-Related Macular Degeneration.

Journal: Genes

Published: June 08, 2025

Two year outcomes of as needed brolucizumab therapy in exudative age related macular degeneration with or without pachychoroid phenotype.

Two year outcomes of as needed brolucizumab therapy in exudative age related macular degeneration with or without pachychoroid phenotype.

Journal: Scientific reports

Published: March 24, 2025

Structural Biomarkers Influencing Drusenoid Pigment Epithelial Detachment Lifecycle and the Development of Late Macular Degeneration.

Structural Biomarkers Influencing Drusenoid Pigment Epithelial Detachment Lifecycle and the Development of Late Macular Degeneration.

Journal: Ophthalmology science

Published: March 08, 2025

Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen.

Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen.

Journal: Scientific reports

Published: March 03, 2025

Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study.

Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study.

Journal: Ophthalmology and therapy

Published: February 20, 2025

Short-Term Outcomes of Three Consecutive Monthly Loading Administrations of Aflibercept 8 Mg for Treatment-Naïve Exudative Age-Related Macular Degeneration.

Short-Term Outcomes of Three Consecutive Monthly Loading Administrations of Aflibercept 8 Mg for Treatment-Naïve Exudative Age-Related Macular Degeneration.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 16, 2025

Clinical and genetic characteristics of simple central serous chorioretinopathy according to age.

Clinical and genetic characteristics of simple central serous chorioretinopathy according to age.

Journal: Ophthalmic genetics

Published: November 11, 2024

Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema.

Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema.

Journal: Photodiagnosis and photodynamic therapy

Published: October 01, 2024

Showing 1-12 of 101

Last Updated: 09/26/2026